US advisers: keep Glaxo diabetes drug on market

GAITHERSBURG, Md, (Reuters) – GlaxoSmithKline Plc’s  diabetes drug Avandia should be allowed to stay on the market  but with additional warnings, U.S. health advisers recommended  yesterday, easing a threat of further costly litigation that  could have followed a ban.

A majority of the 33-member panel of outside experts found  data raised concerns about heart attacks associated with the  widely used pill, but not enough to warrant its withdrawal from  the market.

The Food and Drug Administration will make the final  decision in the coming months and the agency usually follows  recommendations from its advisory committees.

Around the Web